Vimarsana
Biggest News Aggregation in the World

Cdx Zircaix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cdx Zircaix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cdx Zircaix Today - Breaking & Trending Today

Telix Pharmaceuticals Limited: Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging - Vimarsana News

Telix Pharmaceuticals Limited: Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

MELBOURNE, Australia, June 3, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application

Telix Completes TLX250-CDx (Zircaix™) BLA Submission for - Vimarsana News

Telix Completes TLX250-CDx (Zircaix™) BLA Submission for

MELBOURNE, Australia, June 03, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has...

First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent - Vimarsana News

First Patient Dosed in Italian Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent

/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in its named patient program...

Telix 2023 Full Year Results: Inaugural Profit Achieved, - Vimarsana News

Telix 2023 Full Year Results: Inaugural Profit Achieved,

MELBOURNE, Australia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces its results for the...

BLA Submitted to FDA for PET Imaging Agent TLX250-CDx in RCC - Vimarsana News

BLA Submitted to FDA for PET Imaging Agent TLX250-CDx in RCC

A biologics license application seeking the approval of the investigational positron emission tomography imaging agent 89Zr-DFO-girentuximab in clear cell renal cell carcinoma has been submitted to the FDA.